Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) reported preliminary unaudited revenue for the third quarter ended September 30, 2026, expecting total revenue in the range of $9.8 million to $10.0 million.

The figures represent an increase of approximately 85% to 89% compared with $5.3 million in the third quarter of 2025. On a sequential basis, revenue is expected to rise approximately 292% to 300% compared with $2.5 million in the second quarter of 2026.

The preliminary revenue range is approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, compiled as of October 7, 2026.

The company also expects gross margin to exceed 70% for the quarter.

"The expected year-over-year and sequential growth in the third quarter reflects increased commercial activity across our installed base and new customer accounts," said Arun Menawat, CEO and Chairman of Profound Medical.

The figures are preliminary and unaudited, and the company noted that actual revenues may differ. Profound Medical plans to report full third quarter 2026 financial results after market close on November 5, 2026, followed by a conference call at 4:30 p.m. ET.